

Career Development Awards: Epidemiology and Population Sciences Panel A.

Date: April 23–24, 2026.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Magnus A. Azuine, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–4645, magnus.azuine@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; High Impact, Interdisciplinary Science in NIDDK Research Areas and Advancing Research on the Application of Digital Health Technology to the Management of Type 2 DM Study Section Meeting.

Date: April 23, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Dawanna James-Holly, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–2776, dawanna.james-holly@nih.gov.

Name of Committee: Infectious Diseases and Immunology A Integrated Review Group; HIV Molecular Virology, Cell Biology, and Drug Development Study Section.

Date: April 23–24, 2026.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Kenneth A. Roebuck, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5214, MSC 7852, Bethesda, MD 20892, (301) 435–1166, roebuck@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed).

Date: April 23, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Kristina S. Wickham, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 761–5390, kristina.wickham@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Immune Oncology Research (R21).

Date: April 23, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Zhiqiang Zou, Ph.D., MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 276–6372, zouzhiqu@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–25–444: Cancer Center Support Grant.

Date: April 23–24, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Eun Ah Cho, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–3591, EunAh.Cho@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training: Immunology and Infectious Diseases.

Date: April 23, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Caitlin Elizabeth Angela Moyer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 443–4577, caitlin.moyer@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Special Topics in Biochemistry and Biophysics.

Date: April 23–24, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Eduardo Emilio Chufan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 276–7975, chufanee@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 26, 2026

Denise M. Santeufemio,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–06146 Filed 3–30–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

Addition of Preclearance Facility at Billy Bishop Toronto City Airport

AGENCY: U.S. Customs and Border Protection, DHS.

ACTION: General notice.

SUMMARY: This document announces that U.S. Customs and Border Protection (CBP) has opened an additional preclearance facility in Toronto, Ontario, Canada, at the Billy Bishop Toronto City Airport. Preclearance operations allow CBP to inspect and admit travelers and their goods to the United States prior to boarding in a foreign location, creating opportunities for increased security and efficiency. Preclearance enables travelers and their baggage to complete immigration, customs, and agriculture inspections by CBP officers and specialists in a foreign location before boarding a direct flight to the United States, generally eliminating the need for additional CBP (or other U.S. agency) processing or security screening upon arrival.

DATES: The Billy Bishop Toronto City Airport preclearance operations began on March 10, 2026.

FOR FURTHER INFORMATION CONTACT: Joshua Serian, Office of Field Operations, U.S. Customs and Border Protection, 202–713–8649 or Joshua.Serian@cbp.dhs.gov.

SUPPLEMENTARY INFORMATION:

Background

A. Preclearance Operations

CBP preclearance operations have been in existence since 1952.¹ Preclearance facilities are established through the cooperative efforts of CBP, foreign government representatives, and local facility authorities, through signed bilateral treaties known as preclearance agreements.

Each facility is staffed with CBP officers responsible for conducting inspections and examinations in connection with preclearing passengers, crew, and their goods bound for the

¹ See <https://transportgeography.org/contents/chapter6/airport-terminals/pre-clearance-airports-united-states/> (last visited February 10, 2026).

United States. Generally, travelers who are inspected at a preclearance facility are permitted to arrive at a U.S. domestic facility and exit the U.S. domestic terminal upon arrival, or connect directly to a U.S. domestic flight, without further CBP processing.

Preclearance facilities primarily serve to identify known and unknown threats to U.S. national security before arrival into the United States, thereby relieving congestion at federal inspection facilities in the United States, and enhance security in the air environment through the screening and inspection of travelers prior to their arrival in the United States. See 19 CFR 162.8. In Fiscal Year (FY) 2025, over 22 million aircraft travelers were processed at preclearance facilities. This figure represents more than 15 percent of all commercial aircraft travelers cleared by CBP in FY 2025. For FY 2026, CBP projects that an estimated 300,000–350,000 travelers will be processed at the preclearance facility at Billy Bishop Toronto City Airport, and in 10 years, CBP projects that 1 million travelers will be processed at that facility annually.²

B. Toronto, Canada, Preclearance Operations

Preclearance operations have been ongoing in Toronto, Ontario, at Toronto Pearson International Airport since 1952.³ Toronto, Ontario, is listed by city and province as a preclearance office in the CBP regulations in 19 CFR 101.5. Because the city and province are already listed in the regulations, the designation of Billy Bishop Toronto City Airport is being announced here by a notice in the **Federal Register**.

CBP and the Toronto Port Authority signed a Memorandum of Understanding on November 21, 2024, implementing certain aspects of the 2015 Agreement on Land, Rail, Marine, and Air Transport Preclearance between the Government of the United States of America and the Government of Canada to establish another preclearance facility in Toronto, Ontario, in Canada, at Billy Bishop Toronto City Airport. Preclearance operations at Billy Bishop Toronto City Airport are a second preclearance facility in the Toronto, Ontario, preclearance office. Operations at this new facility began on March 10,

² Information in this paragraph regarding preclearance facility processing numbers was provided by CBP subject matter experts on November 5, 2025.

³ See <https://www.canada.ca/en/news/archive/2015/03/canada-united-states-sign-historic-preclearance-agreement.html> (last visited February 10, 2026). See also 8 FR 8099 (1943) and T.D. 77–241 (42 FR 54936, Oct. 12 1977).

2026. CBP will also list this new location on its website.⁴ The Billy Bishop Toronto City Airport preclearance facility is open for use by commercial flights. For a list of preclearance offices, please see 19 CFR 101.5.

Signing Authority

The authority of the Secretary of the Treasury with respect to CBP regulations that are not related to customs revenue was transferred to the Secretary of Homeland Security pursuant to section 403(l) of the Homeland Security Act of 2002. This document is being issued in accordance with DHS Delegation Order 7010.3, Revision 03.2, which delegates to the Commissioner of CBP the authority to publish notices relating to the administration of the activities of CBP.

Rodney S. Scott, the Commissioner, having reviewed and approved this document, has delegated the authority to electronically sign this document to the Director of the Regulations and Disclosure Law Division of CBP, for purposes of publication in the **Federal Register**.

Robert F. Altneu,

Director, Regulations & Disclosure Law Division, Regulations & Rulings, Office of Trade, U.S. Customs and Border Protection.

[FR Doc. 2026–06164 Filed 3–30–26; 8:45 am]

BILLING CODE 9111–14–P

DEPARTMENT OF THE INTERIOR

Geological Survey

[Docket No. USGS–ECO–2026–0001; OMB Control Number 1028–0116; GX.25.WB00.COM16.00]

Agency Information Collection Activities; Alaska Beak Deformity Observations

AGENCY: U.S. Geological Survey, Interior.

ACTION: Notice of information collection; request for comment.

SUMMARY: In accordance with the Paperwork Reduction Act (PRA) of 1995, U.S. Geological Survey (USGS) is proposing to renew an information collection as part of the ongoing research in North American birds. Members of the public provide observation reports of birds with deformities from Alaska and other regions.

⁴ A complete list of preclearance locations is available at: <https://www.cbp.gov/travel/preclearance> (last visited on January 5, 2026).

DATES: Interested persons are invited to submit comments on or before June 1, 2026.

ADDRESSES: You may submit comments by one of the following methods:

■ **Internet:** <https://www.regulations.gov>. Search for and submit comments on Docket No. USGS–ECO–2026–0001.

■ **U.S. Mail:** USGS, Information Collections Clearance Officer, 12201 Sunrise Valley Drive, MS 159, Reston, VA 20192.

FOR FURTHER INFORMATION CONTACT: Colleen Handel by email at cmhandel@usgs.gov, or by telephone at 907–786–7181. Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States.

SUPPLEMENTARY INFORMATION: In accordance with the PRA of 1995 (44 U.S.C. 3501 *et seq.*) and 5 CFR 1320.8(d)(1), all information collections require approval under the PRA. An agency may not conduct or sponsor, nor is an individual required to respond to a collection of information unless it displays a currently valid OMB control number.

As part of our continuing effort to reduce paperwork and respondent burdens, we invite the public and other Federal agencies to comment on new, proposed, revised, and continuing collections of information. This helps us assess the impact of our information collection requirements and minimize the public's reporting burden. It also helps the public understand our information collection requirements and provide the requested data in the desired format.

We are especially interested in public comment addressing the following:

- (1) Whether or not the collection of information is necessary for the proper performance of the functions of the agency, including whether or not the information will have practical utility;
- (2) The accuracy of our estimate of the burden for this collection of information, including the validity of the methodology and assumptions used;
- (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and
- (4) How the agency might minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic,